S5701

SR 49059

≥97% (HPLC)

• Synonyme(s) : (2S)-1-[[(2R,3S)-5-Chloro-3-(2-chlorophenyl)-1-[(3,4-dimethoxyphenyl)sulfonyl]-2,3-dihydro-3-hydroxy-1H-indol-2-yl]carbonyl]-2-pyrrolidinecarboxamide, SR49059
• Formule empirique (notation de Hill) : C₂₈H₂₇Cl₂N₃O₇S
• CAS Number: 150375-75-0
• Poids moléculaire : 620.50
• Numéro MDL: MFCD00922133
• Code UNSPSC : 51111800
• ID de substance PubChem : 329824460
• Nomenclature NACRES : NA.77

Propriétés

• Niveau de qualité: 100
• Essai: ≥97% (HPLC)
• Forme: powder
• Activité optique: [α]/D -180 to -190°, c = 0.3 in chloroform-d
• Couleur: white to off-white
• Solubilité: DMSO: ≥10 mg/mL
• Auteur: Sanofi Aventis
• Température de stockage: 2-8°C
• Chaîne SMILES: COc1ccc(cc1OC)S(=O)(=O)N2[C@@H](C(=O)N3CCC[C@H]3C(N)=O)[C@@](O)(c4ccccc4Cl)c5cc(Cl)ccc25
• InChI: 1S/C28H27Cl2N3O7S/c1-39-23-12-10-17(15-24(23)40-2)41(37,38)33-21-11-9-16(29)14-19(21)28(36,18-6-3-4-7-20(18)30)25(33)27(35)32-13-5-8-22(32)26(31)34/h3-4,6-7,9-12,14-15,22,25,36H,5,8,13H2,1-2H3,(H2,31,34)/t22-,25-,28+/m0/s1
• Clé InChI: CEBYCSRFKCEUSW-NAYZPBBASA-N
• Informations sur le gène: human ... AVPR1A(552), OXTR(5021)

Description

Application

SR 49059 has been used to study the V1AR (vasopressin type 1A receptor) signaling mediated β adrenergic receptor responsiveness and its contribution to the development of heart failure.

SR 49059 may be used in Arginine Vasopressin (AVP) V1a-receptor-mediated cell signaling studies.

Actions biochimiques/physiologiques

SR 49059 is a potent and selective Arginine Vasopressin (AVP) V1a-receptor antagonist.

SR 49059 is a potent and selective Arginine Vasopressin (AVP) V1a-receptor antagonist. AVP is a hormone that plays an important part in circulatory and water homoeostasis and is important in renal hemodynamic alterations, water retention, and cardiac remodeling in congestive heart failure (CHF). There are three AVP receptor subtypes V1a, V1b, and V2. All belong to the large rhodopsin-like G-protein-coupled receptor family. V(1a) antagonists improve water balance and cardiac hypertrophy in CHF and might be beneficial for the treatment of water retention and cardiac remodeling in CHF. SR 49059 has also shown initial positive results in the treatment of Raynaud′s disease, dysmenorrhoea, and tocolysis.

Caractéristiques et avantages

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Informations sur la sécurité

• Code de la classe de stockage: 11 - Combustible Solids
• Classe de danger pour l'eau (WGK): nwg
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable